Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 8035013, 8 pages
https://doi.org/10.1155/2017/8035013
Clinical Study

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

1Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, France
2Centre d’Imagerie et de Laser, 11 rue Antoine Bourdelle, Paris, France
3Ophthalmology Department, Pitié Salpétrière Hospital, DHU Vision and Handicaps, Paris VI University, Paris, France

Correspondence should be addressed to Audrey Giocanti-Auregan; rf.oohay@itnacoigyerdua

Received 5 April 2017; Revised 19 June 2017; Accepted 16 July 2017; Published 16 August 2017

Academic Editor: Thomas Bertelmann

Copyright © 2017 Antoine Herbaut et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Romero-Aroca, “Managing diabetic macular edema: the leading cause of diabetes blindness,” World Journal of Diabetes, vol. 2, pp. 98–104, 2011. View at Publisher · View at Google Scholar
  2. J. W. Yau, S. L. Rogers, R. Kawasaki et al., “Global prevalence and major risk factors of diabetic retinopathy,” Diabetes Care, vol. 35, pp. 556–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Delcourt, P. Massin, and M. Rosilio, “Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population,” Diabetes & Metabolism, vol. 35, pp. 431–438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., “Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE,” Ophthalmology, vol. 119, pp. 789–801, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. F. Korobelnik, D. V. Do, U. Schmidt-Erfurth et al., “Intravitreal aflibercept for diabetic macular edema,” Ophthalmology, vol. 121, pp. 2247–2254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Hrarat, F. Fajnkuchen, M. Boubaya et al., “Outcomes after a 1-year treatment with ranibizumab for diabetic macular edema in a clinical setting,” Ophthalmologica, vol. 236, pp. 207–214, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. D. S. Boyer, Y. H. Yoon, R. Belfort Jr. et al., “Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema,” Ophthalmology, vol. 121, pp. 1904–1914, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Rahimy, A. Shahlaee, M. A. Khan et al., “Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema,” American Journal of Ophthalmology, vol. 164, pp. 118–127.e2, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. E. H. Wood, P. A. Karth, D. M. Moshfeghi, and T. Leng, “Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab,” Ophthalmic Surgery Lasers Imaging Retina, vol. 46, pp. 950–954, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. L. S. Lim, W. Y. Ng, R. Mathur et al., “Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab,” Clinical Ophthalmology (Auckland, N.Z.), vol. 9, pp. 1715–1718, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Papadopoulos, J. Martin, Q. Ruan et al., “Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab,” Angiogenesis, vol. 15, pp. 171–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. P. U. Dugel, J. Hillenkamp, S. Sivaprasad et al., “Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials,” Clinical Ophthalmology (Auckland, N.Z.), vol. 10, pp. 1103–1110, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Gutiérrez-Benítez, E. Millan, L. Arias, P. Garcia, E. Cobos, and M. Caminal, “Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy,” Archivos de la Sociedad Espanola de Oftalmologia, vol. 90, pp. 475–480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Zhioua, O. Semoun, F. Lalloum, and E. H. Souied, “Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema,” Retina (Philadelphia, Pa.), vol. 35, pp. 1429–1435, 2015. View at Publisher · View at Google Scholar
  15. E. Pacella, A. R. Vestri, R. Muscella et al., “Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema,” Clinical Ophthalmology (Auckland, N.Z.), vol. 7, pp. 1423–1428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Brown, U. Schmidt-Erfurth, D. V. Do et al., “Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies,” Ophthalmology, vol. 122, pp. 2044–2052, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Fassnacht-Riederle, M. Becker, N. Graf, and S. Michels, “Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 252, pp. 1705–1709, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Forooghian, E. Y. Chew, C. B. Meyerle, C. Cukras, and W. T. Wong, “Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis,” Acta Ophthalmologica, vol. 89, pp. e206–e207, 2011. View at Publisher · View at Google Scholar · View at Scopus